Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Gro...( BASINGSTOKE England and PHILADELP...)

BASINGSTOKE, England and PHILADELPHIA, February 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 - a year which has seen significant growth in launched products.
- All $ values are US$

Financial Highlights

2007 Full Year Q4 2007

- Product sales up 41% to $2,170m - Product sales up 55% to $661m

- New product sales $489m, 23% of product - New product sales $210m, 32%

sales(1) of product sales (1)

- Total revenues up 36% to $2,436m - Total revenues up 46% to

$725m

- Non GAAP Earnings per ADS up 38% to - Non GAAP Earnings per ADS up

$2.95 67% to $0.94

- US GAAP Earnings per ADS down 592% to - US GAAP Earnings per ADS up

-$8.06 175% to $1.11

- Dividend up 20% (in US$ terms)

(1) New product sales include VYVANSE, LIALDA/MEZAVANT, DYNEPO, ELAPRASE, FOSRENOL and DAYTRANA

Matthew Emmens, Chief Executive Officer, commented:

"Shire had an excellent 2007, growing sales from our portfolio of both new and established products by a total of 41% and raising revenue guidance throughout the course of the year. We generated substantial cash inflows from operations of $475 million, after expending $156 million on the acquisition of new product candidates in both our Human Genetic Therapies and Specialty Pharmaceutical businesses. Based on these strong results we were able to bring forward several new R&D programs.

During the year, we undertook three major new product launches - VYVANSE, LIALDA / MEZAVANT and DYNEPO - which have gone well and also continued the roll-out of ELAPRASE and FOSRENOL into new geographies. These products, together with
'/>"/>